Choose a Condition to Learn More
Enrolling
Sponsor: RegenexBio
Protocol Number: RGX-314-3101A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD.
Sponsor: RegenexBio
Protocol Number: RRGX-314-2104A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD
Sponsor: Affamed
Protocol Number: AM712E1001A Prospective, Multi-Center, Open-label, Sequential, Multiple Ascending-Dose and Randomized Dose-Expansion Cohorts Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AM712 Following Intravitreal Administration in Patients with Neovascular Age-related Macular Degeneration.
Sponsor: Adverum Biotech
Protocol Number: ADVM-022-11A Multi-Center, Randomized, Open Label Study of ADVM-022 (AAV. 7m8-aflibercept) in Neovascular (Wet) Age-related Macular Degeneration (nAMD)
Sponsor: Notal Vision
Protocol Number: C2021.006The Evaluation of the Agreement and Precision of the Notal Vision Home OCT in the Automatic Fluid Quantification in Patients with NV-AMD
Sponsor: Opthea
Protocol Number: OPT-302-1004A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Ranibizumab, Compared with Ranibizumab Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)
Ongoing
Sponsor: Amgen
Protocol Number: ABP938A Randomized, Double-masked, Phase 3 Study of ABP 938 Efficacy and Safety Compared to Aflibercept (Eylea®) in Subjects with Neovascular Age-related Macular Degeneration
Sponsor: Genentech
Protocol Number: GR42691A Multicenter, Open-Label Extension Study to evaluate the long-term safety and tolerability of faricimab in patients with neovascular age-related macular degeneration (Avonelle-X)
Sponsor: Adverum Biotech
Protocol Number: ADVM-022-07A Long-term study of ADVM-022 in Neovascular (WET) AMD- Optic Extension
Sponsor: Genentech
Protocol Number: GR40549A Multicenter, Open-Label Extension study to evaluate the long-term safety and tolerability of the port delivery system with Ranibizumab in Patients with Neovascular age-related macular degeneration
Enrolling
Sponsor: Ionis
Protocol Number: 696844-CS5A Phase 2, Randomized, Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRX, an Antisense Inhibitor of Complement Factor B, in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
Sponsor: Janssen
Protocol Number: HMR59?A Phase 2b, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-Controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Advanced Age-related Macular Degeneration (AMD)
Sponsor: Genetech
Protocol Number: GR42163A Phase Ia, Multicenter, open-label, single-dose, dose-escalation study of the safety, tolerability, Pharmacokinetics, and immunogenicity of intravitreal injections of R07303359 in Patients with Geographic Atrophy secondary to age-related macular degeneration
Ongoing
Sponsor: Alkeus
Protocol Number: ALK-001A Phase 2/3 Multicenter, Randomized, Double-masked, Parallel-group, Placebo-controlled Study to Investigate the Safety, Pharmacokinetics, Tolerability, and Efficacy of ALK-001 in Geographic Atrophy Secondary to Age-related Macular Degeneration
Sponsor: Apellis
Protocol Number: APL-2-305A Phase 3, Open-Label, Multicenter, Extension study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in subjects with Geographic Atrophy Secondary to Age-Related Macular Degeneration
Sponsor: Iveric
Protocol Number: ISEE2008A Phase 3 Multicenter, Randomized, Double-Masked, Sham-Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients with Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Ongoing
Sponsor: Genentech
Protocol Number: GR41675A Phase III, Multicenter, Randomized study of the efficacy, safety, and Pharmacokinetics of the Port Delivery System with Ranibizumab in Patients with Diabetic Retinopathy (Pavilion)
Ongoing
Sponsor: Genentech
Protocol Number: GR41986A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to evaluate the efficacy and safety of Faricimab in Patients with Macular Edema secondary to Central Retinal or Hemiretinal vein occlusion
Enrolling
Sponsor: Genentech
Protocol Number: BP43445A phase II, multicenter, randomized, double masked, active comparator-controlled study to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of RO7200220 administered intravitreally in patients with diabetic macular edema
Ongoing
Sponsor: Kodiak
Protocol Number: KS301P104A Prospective, Randomized, Double-masked, Active comparator-controlled, multi-center, two-arm, Phase 3 Study to evaluate the efficacy and safety of Intravitreal KSI-301 compared with Intravitreal Aflibercept in Patients with Visual Impairment secondary to treatment-naive diabetic macular edema (DME)
Sponsor: Genentech
Protocol Number: GR40550A phase III, multicenter, randomized, visual assessor-masked, active-comparator study of the efficacy, safety, and pharmacokinetics of the port delivery system with ranibizumab in patients with diabetic macular edema (PAGODA)
Sponsor: Genentech
Protocol Number: GR41987A multicenter, open-label extension study to evaluate the long-term safety and tolerability of faricimab in patients with diabetic macular edema
Sponsor: FFB
Protocol Number: ProEyS024Rate of Progression in EYS Related Retinal Degeneration (Pro-EYS)
Enrolling
Sponsor: Acelyrin
Protocol Number: 21103A Phase 2 Dose-finding Study to Evaluate the Efficacy, Safety, and Immunogenicity of Izokibep in Subjects with With Non-infectious Intermediate Uveitis, Posterior Uveitis or Panuveitis
Sponsor: Priovant
Protocol Number: PVT-2201-201A Phase 2 Randomized, Double-Masked, Dose-Ranging Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults with Active Non-Infectious Intermediate-, Posterior-, and Panuveitis
Ongoing
Sponsor: UCSF
Protocol Number: 17-23987Adalimumab in Juvenile Idiopathic Arthritis-associated uveitis Stopping Trial (ADJUST)